Homeostatic model assessment
Homeostatic Model Assessment (HOMA) is a method used in the field of physiology and medicine to quantify insulin resistance and beta-cell function. It was first described in a 1985 paper by Matthews et al. in the journal Diabetologia.
Overview[edit]
The HOMA model is based on the physiological principle of homeostasis, the body's ability to maintain a stable internal environment despite external changes. In the context of glucose metabolism, homeostasis involves a balance between insulin production by the pancreas's beta cells and insulin sensitivity in peripheral tissues.
HOMA uses fasting plasma glucose and insulin concentrations to calculate indices of insulin resistance (HOMA-IR) and beta-cell function (HOMA-β). These indices provide a simple and inexpensive way to assess these key aspects of glucose metabolism, which are often disrupted in conditions such as type 2 diabetes and metabolic syndrome.
Calculation[edit]
The original HOMA model calculates HOMA-IR and HOMA-β as follows:
- HOMA-IR = (fasting insulin [μU/mL] × fasting glucose [mmol/L]) / 22.5
- HOMA-β = (20 × fasting insulin [μU/mL]) / (fasting glucose [mmol/L] - 3.5)
These equations assume a normal reference range for fasting insulin of 5-10 μU/mL and for fasting glucose of 3.5-5.5 mmol/L.
Clinical Use[edit]
HOMA indices are widely used in both research and clinical settings to assess insulin resistance and beta-cell function. They can help identify individuals at risk of developing type 2 diabetes and monitor the effectiveness of treatments aimed at improving insulin sensitivity or beta-cell function.
However, HOMA is not without limitations. It requires accurate measurement of fasting insulin and glucose, which can be influenced by factors such as diet, physical activity, and stress. Furthermore, it assumes a constant relationship between insulin and glucose, which may not hold true in all individuals or disease states.
See Also[edit]
References[edit]
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian